The Summary of Product Characteristics (SPC) for Talzenna, hard capsules (0.1mg, 0.25 mg or 1mg) is available here.
Breast cancer
Talzenna (talazoparib) is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments (see section 5.1 of the SPC).
Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.
Prostate cancer
Talzenna (talazoparib) is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
*Contact Medical Information. 09h - 18h Monday to Friday.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to the Pfizer-BioNTech COVID-19 vaccines, click the link below:
www.pfizersafetyreporting.com
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please contact Pfizer pharmacovigilance at
[email protected].
You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr